A robust RNAi nanoplatform for precise activation of cGAS-STING pathway and effective immune checkpoint blockade to potentiate cancer immunotherapy | Synapse
March 3, 2026
A robust RNAi nanoplatform for precise activation of cGAS-STING pathway and effective immune checkpoint blockade to potentiate cancer immunotherapy
Key Points
Enhanced activation of the cGAS-STING pathway leads to improved immune responses in cancer treatment.
The RNA interference technology was pivotal in achieving precise control of the immune checkpoint blockade.
Utilization of a nanoplatform allows for robust delivery of therapeutic agents directly to target cells.
This approach suggests a promising strategy for maximizing the efficacy of cancer immunotherapies.